共 128 条
[1]
Ferrara N(2005)Angiogenesis as a therapeutic target Nature 438 967-974
[2]
Kerbel RS(2004)Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2335-2342
[3]
Hurwitz H(2005)Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer J Clin Oncol 23 3502-3508
[4]
Fehrenbacher L(2003)Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer J Clin Oncol 21 60-65
[5]
Novotny W(2005)Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer J Clin Oncol 23 3706-3712
[6]
Cartwright T(2008)Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 2013-2019
[7]
Hainsworth J(2008)Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study J Clin Oncol 26 689-690
[8]
Heim W(2008)Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study J Clin Oncol 26 3523-3529
[9]
Berlin J(2001)Meta-analyses of randomised clinical trials in oncology Lancet Oncol 2 475-482
[10]
Baron A(2006)Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients Cancer 106 2337-2344